March 28, 2012
A California district court on Tuesday ruled again that Abbott Laboratories' patent covering blood glucose monitoring technology was unenforceable, finding that an Abbott attorney and a scientist committed inequitable conduct by concealing information about the patent from the U.S. Patent and Trademark Office.